myNEO Therapeutics
myNEO Therapeutics develops an ImmunoEngine platform for personalized cancer vaccine neoantigen discovery, epitope prediction, and mRNA codon optimization.
myNEO Therapeutics' ImmunoEngine platform combines immunology expertise with AI-driven technologies for personalized neoantigen discovery in cancer vaccines and T-cell therapies, mRNA codon optimization, ADA risk prediction, and multi-epitope construct design. The company serves vaccine developers, biologics innovators, and pharma partners, and offers a proprietary asset library of immunotherapy targets for partnering and licensing.
Key People
Cedric Bogaert - Co-Founder, CEO